Gynecologic Cancers

As prevalence of HPV within the population rises, incidence of HPV-related cancers is expected to rise.

Fewer people are dying from cancer than years ago, according to a recent study.

The FDA has granted approval for the PARP inhibitor niraparib for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial repsponse to platinum-based chemotherapy.

For patients with BRCA+ ovarian cancer, olaparib in the maintenance setting has shown impressive progression free survival benefits.

When we, as navigators, wake up each morning, we never know what we will be asked to accomplish in the care of our patients and their families.

The risk of dying from cervical cancer appears to be much higher than previously thought, and racial disparities have been greatly underestimated.

According to a recent survey, the main causes for a lack of HPV vaccine uptake are a lack of knowledge and a failure by healthcare providers to recommend it.

After chemotherapy proved unsuccessful, one patient entered a clinical trial of a new combination for immunotherapy for her ovarian cancer.

A multidisciplinary team went to Botswana to bring more effective treatment to patients with cervical cancer.

Survivors of endometrial cancer are at higher risk for long-term cardiovascular problems such as phlebitis, thrombophlebitis, pulmonary heart disease, hypotension and atrial fibrillation.

In a current phase II/III clinical trial for patients with advanced, recurrent, platinum-resistant ovarian cancer, the novel agent fasbretablin tromethamine is combined with bevacizumab (Avastin) and either paclitaxel or pegylated liposomal doxorubicin.

A recent study suggested that intentional weight loss could decrease the risk of endometrial cancer.

Gynecologic oncology and reproductive medicine expert discusses the new HPV vaccine recommendations and the importance of awareness for all HPV-caused cancers.

Krista Qualmann discusses hereditary cancer syndromes.

A recent study evaluated the relationship between polycystic ovarian syndrome (PCOS), long or irregular periods, and ovarian cancer risk.

TESARO, manufacturer of the PARP inhibitor niraparib has opened an expaned access program (EAP) for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after complete or partial response to platinum-based chemotherapy.

A recent study shows that expedited surgery for patients with endometrial cancer is linked to an increased risk of mortality.

A recent study links NSAID use to an increased risk of endometrial carcinoma­–specific mortality.

FDA grants approval to rucaparib for BRCA-positive, advanced ovarian cancer.

SHARE online support communities for patients with ovarian cancer, breast cancer, and metastatic breast cancer.

The FDA has expanded the approval of bevacizumab to include platinum-sensitive recurrent ovarian cancer.

Krista Qualmann discusses the nurse's role once a patient has gone for genetic testing.

Due to a dramatic reduction of risk for cervical cancer in women who have received the HBV vaccine, there may be a reduction of screening for those women.

Expert Kristin Zorn, MD discusses the importance that genetics plays in oncology, and the why genetic counseling and testing are vital.

Neoadjuvant chemotherapy (NACT) in treating advanced ovarian cancer has brought improvement s to quality of life and morbidity, but there are still issues within its use, such as choosing the best candidates.